Treatment with a novel oleic-acid–dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats
Authors:
- Juan M. DecaraJDJuan M. Decara
- Francisco Javier PavónFrancisco Javier Pavón
- Juan SuárezJuan Suárez
- Miguel Romero-CuevasMiguel Romero-Cuevas
- Elena BaixerasEBElena Baixeras
- Patricia RiveraPRPatricia Rivera
- Ana L. GavitoAGAna L. Gavito
- Jesús JoglarJJJesús Joglar
- Rafael de la TorreRTRafael de la Torre
- Fernando Rodríguez de FonsecaFFFernando Rodríguez de Fonseca
Open Access
- 1 October 2015
- journal article
- research article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 8 (10) , 1213-1225
Abstract
Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no effective treatments for this pathology apart from the use of classical fibrates. In this study, we have characterized the in vivo effects of a novel conjugation of oleic acid with an amphetamine derivative (OLHHA) in an animal model of genetic obesity. Lean and obese Zucker rats received a daily intraperitoneal administration of OLHHA (5 mg kg−1) for 15 days. Plasma and liver samples were collected for the biochemical and molecular biological analyses, including both immunohistochemical and histological studies. The expression of key enzymes and proteins that are involved in lipid metabolism and energy homeostasis was evaluated in the liver samples. The potential of OLHHA to produce adverse drug reactions or toxicity was also evaluated through the monitoring of interactions with hERG channel and liver cytochrome. We found that OLHHA is a drug with a safe pharmacological profile. Treatment for 15 days with OLHHA reduced the liver fat content and plasma triglyceride levels, and this was accompanied by a general improvement in the profile of plasma parameters related to liver damage in the obese rats. A decrease in fat accumulation in the liver was confirmed using histological staining. Additionally, OLHHA was observed to exert anti-apoptotic effects. This hepatoprotective activity in obese rats was associated with an increase in the mRNA and protein expression of the cannabinoid type 1 receptor and a decrease in the expression of the lipogenic enzymes FAS and HMGCR primarily. However, changes in the mRNA expression of certain proteins were not associated with changes in the protein expression (i.e. L-FABP and INSIG2). The present results demonstrate that OLHHA is a potential anti-steatotic drug that ameliorates the obesity-associated fatty liver and suggest the potential use of this new drug for the treatment of non-alcoholic fatty liver disease.Keywords
This publication has 34 references indexed in Scilit:
- The Highs and Lows of Cannabinoid Receptor Expression in Disease: Mechanisms and Their Therapeutic ImplicationsPharmacological Reviews, 2011
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re‐feedingBritish Journal of Pharmacology, 2009
- Endocannabinoids and the Control of Energy HomeostasisJournal of Biological Chemistry, 2008
- Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in miceJournal of Clinical Investigation, 2008
- Nonalcoholic Fatty Liver Disease: From Steatosis to CirrhosisHepatology, 2006
- Apoptosis: a mechanism of acute and chronic liver injuryGut, 2005
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003
- A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATIONCanadian Journal of Biochemistry and Physiology, 1959